Compare Stocks: LQDA, VTRS, JAZZ, and NBIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAZZ Jazz Pharmaceuticals	$246.81 -0.3%	$249.14	$123.88 ▼ $266.38	$16.02B	0.36	1.07 million shs	321,867 shs
LQDA Liquidia	$68.66 +0.0%	$78.51	$21.15 ▼ $93.61	$6.15B	0.53	1.58 million shs	900,232 shs
NBIX Neurocrine Biosciences	$155.64 -1.7%	$165.98	$122.14 ▼ $186.12	$15.82B	0.38	1.15 million shs	933,449 shs
VTRS Viatris	$16.88 -0.4%	$16.77	$9.43 ▼ $18.39	$19.39B	0.89	8.99 million shs	5.73 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAZZ Jazz Pharmaceuticals	-0.31%	+0.93%	-5.64%	+3.45%	+87.37%
LQDA Liquidia	+0.04%	+1.43%	-22.96%	+11.01%	+134.98%
NBIX Neurocrine Biosciences	-1.71%	+1.03%	-3.63%	-5.03%	+14.35%
VTRS Viatris	-0.35%	+3.30%	-4.36%	+6.30%	+60.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAZZ Jazz Pharmaceuticals	$246.81 -0.3%	$249.14	$123.88 ▼ $266.38	$16.02B	0.36	1.07 million shs	321,867 shs
LQDA Liquidia	$68.66 +0.0%	$78.51	$21.15 ▼ $93.61	$6.15B	0.53	1.58 million shs	900,232 shs
NBIX Neurocrine Biosciences	$155.64 -1.7%	$165.98	$122.14 ▼ $186.12	$15.82B	0.38	1.15 million shs	933,449 shs
VTRS Viatris	$16.88 -0.4%	$16.77	$9.43 ▼ $18.39	$19.39B	0.89	8.99 million shs	5.73 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAZZ Jazz Pharmaceuticals	-0.31%	+0.93%	-5.64%	+3.45%	+87.37%
LQDA Liquidia	+0.04%	+1.43%	-22.96%	+11.01%	+134.98%
NBIX Neurocrine Biosciences	-1.71%	+1.03%	-3.63%	-5.03%	+14.35%
VTRS Viatris	-0.35%	+3.30%	-4.36%	+6.30%	+60.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JAZZ Jazz Pharmaceuticals	3.00	Buy	$285.44	15.65% Upside
LQDA Liquidia	2.45	Hold	$98.08	42.85% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$201.05	29.17% Upside
VTRS Viatris	2.43	Hold	$17.50	3.67% Upside

Current Analyst Ratings Breakdown

Latest LQDA, VTRS, JAZZ, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
9/3/2026	NBIX Neurocrine Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$249.00 ➝ $253.00
8/28/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$299.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$277.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$283.00 ➝ $322.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$300.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$287.00 ➝ $300.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$264.00 ➝ $281.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$292.00 ➝ $310.00
8/25/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/20/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JAZZ Jazz Pharmaceuticals	$4.27B	3.75	$16.26 per share	15.18	$73.97 per share	3.34
LQDA Liquidia	$158.32M	38.82	N/A	N/A	$2.18 per share	31.50
NBIX Neurocrine Biosciences	$2.86B	5.53	$5.01 per share	31.05	$36.34 per share	4.28
VTRS Viatris	$14.30B	1.36	$7.37 per share	2.29	$12.42 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	17.02	11.13	0.22	20.45%	33.97%	13.02%	11/4/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	50.12	15.68	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	22.82	16.45	0.73	20.91%	22.43%	15.64%	10/27/2026 (Estimated)
VTRS Viatris	-$3.51B	-$0.36	N/A	6.35	1.52	-2.79%	20.02%	8.02%	11/5/2026 (Estimated)

Latest LQDA, VTRS, JAZZ, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	VTRS Viatris	$0.6010	$0.69	+$0.0890	-$0.10	$3.68 billion	$3.76 billion
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
VTRS Viatris	$0.48	2.84%	N/A	N/A	N/A

Latest LQDA, VTRS, JAZZ, and NBIX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/3/2026	VTRS Viatris	quarterly	$0.12	2.94%	8/21/2026	8/21/2026	9/16/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
LQDA Liquidia	0.63	2.31	2.12
NBIX Neurocrine Biosciences	N/A	1.87	1.75
VTRS Viatris	0.81	1.58	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JAZZ Jazz Pharmaceuticals	89.14%
LQDA Liquidia	64.54%
NBIX Neurocrine Biosciences	92.59%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
JAZZ Jazz Pharmaceuticals	4.10%
LQDA Liquidia	25.60%
NBIX Neurocrine Biosciences	4.60%
VTRS Viatris	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable
VTRS Viatris	30,000	1.15 billion	1.15 billion	Optionable

LQDA, VTRS, JAZZ, and NBIX Headlines

Recent News About These Companies

Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?

August 29, 2026 | finance.yahoo.com

Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

August 28, 2026 | proactiveinvestors.co.uk

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

August 27, 2026 | zacks.com

Viatris' China Policy Concerns Overstated, UBS Says

August 19, 2026 | finance.yahoo.com

Here's Why Viatris (VTRS) is a Strong Value Stock

August 18, 2026 | zacks.com

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M

August 6, 2026 | seekingalpha.com

Viatris (NASDAQ:VTRS) posts better-than-expected sales in Q2 CY2026

August 6, 2026 | msn.com

Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

August 6, 2026 | zacks.com

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

August 6, 2026 | zacks.com

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

August 6, 2026 | zacks.com

Viatris Reports Second-Quarter 2026 Financial Results

August 6, 2026 | prnewswire.com

Viatris (VTRS) Q2 earnings report preview: What to look for

August 5, 2026 | msn.com

Viatris Q2 preview: Analysts see profits softening amid pressure on generics business

August 5, 2026 | msn.com

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

August 5, 2026 | zacks.com

Is Wall Street bullish or bearish on Viatris stock?

August 4, 2026 | msn.com

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

August 4, 2026 | zacks.com

Viatris Announces Quarterly Dividend

August 4, 2026 | prnewswire.com

Viatris: A Reasonable Valuation

August 3, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, VTRS, JAZZ, and NBIX Company Descriptions

Jazz Pharmaceuticals NASDAQ:JAZZ

$246.81 -0.76 (-0.31%)

As of 09/4/2026 04:00 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Liquidia NASDAQ:LQDA

$68.66 +0.03 (+0.04%)

As of 09/4/2026 04:00 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Neurocrine Biosciences NASDAQ:NBIX

$155.64 -2.71 (-1.71%)

As of 09/4/2026 04:00 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Viatris NASDAQ:VTRS

$16.88 -0.06 (-0.35%)

As of 09/4/2026 04:00 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LQDA, VTRS, JAZZ, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LQDA, VTRS, JAZZ, and NBIX Earnings

Compare Dividends

Latest LQDA, VTRS, JAZZ, and NBIX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LQDA, VTRS, JAZZ, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, VTRS, JAZZ, and NBIX Company Descriptions

Jazz Pharmaceuticals NASDAQ:JAZZ

Liquidia NASDAQ:LQDA

Neurocrine Biosciences NASDAQ:NBIX

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LQDA, VTRS, JAZZ, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LQDA, VTRS, JAZZ, and NBIX Earnings

Compare Dividends

Latest LQDA, VTRS, JAZZ, and NBIX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LQDA, VTRS, JAZZ, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, VTRS, JAZZ, and NBIX Company Descriptions

Jazz Pharmaceuticals NASDAQ:JAZZ

Liquidia NASDAQ:LQDA

Neurocrine Biosciences NASDAQ:NBIX

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools